Jibiki, Aya

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Research Associate/Assistant Professor/Instructor

E-mail Address

E-mail address

Career 【 Display / hide

  • 2005.04
    -
    2014.07

    University of Tsukuba Hospital, Department of Pharmacy, Chief

Academic Background 【 Display / hide

  • 1999.04
    -
    2003.03

    Meiji Pharmaceutical University, 薬学部

    University, Graduated

  • 2003.04
    -
    2005.03

    Chiba University, 大学院薬学研究院

    Graduate School, Completed, Master's course

Licenses and Qualifications 【 Display / hide

  • Pharmacist license, 2003.06

 

Research Areas 【 Display / hide

  • Medical pharmacy

Research Keywords 【 Display / hide

  • proper use of steroids, connective tissue disease, menopausal syndrome, osteoporosis, bitter-taste masking of medicine

  • 更年期障害に対する薬物治療

  • Kampo Medicine

  • 膠原病

  • 医薬品の苦味マスキング

display all >>

Research Themes 【 Display / hide

  • 更年期障害に対する漢方製剤処方実態調査および漢方治療不応例の要因分析, 

    2018.02
    -
    2021.03

     View Summary

    更年期障害の女性に対する漢方製剤処方実態調査を行うとともに、漢方治療の不応例についてその要因を分析し、更年期障害に対する漢方製剤を中心とした薬物治療の最適化、個別化につなげていく

  • グルココルチコイド(GC)使用膠原病患者におけるGC誘発性糖尿病に対する処方実態調査および治療薬の有用性の検討, 

    2017.12
    -
    2020.03

     View Summary

    GC製剤を使用している膠原病患者において、糖尿病(GC誘発性糖尿病)の発現状況、GC誘発性糖尿病に対する治療薬の処方実態や臨床検査値等について調査し、各種糖尿病治療薬のGC誘発性糖尿病に対する有用性について検討する。

 

Books 【 Display / hide

  • こどもと薬のQ&A続

    石川洋一 監修 小児薬物療法研究会 編集(編集協力者:地引 綾), じほう, 2018.09

Papers 【 Display / hide

  • Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

    Ogiwara T., Kawazoe H., Egami S., Hashimoto H., Saito Y., Sakiyama N., Ohe Y., Yamaguchi M., Furukawa T., Hara A., Hiraga Y., Jibiki A., Yokoyama Y., Suzuki S., Nakamura T.

    Frontiers in Oncology (Frontiers in Oncology)  11 2021.11

    Research paper (scientific journal), Joint Work

     View Summary

    Background: Nivolumab and pembrolizumab are the standard treatments for patients with advanced non-small-cell lung cancer (NSCLC). While there are reports on several inflammatory indices and the prognosis of patients with cancer, no study has combined baseline medication with the neutrophil-to-lymphocyte ratio (NLR) to predict clinical outcomes. This study investigated the efficacy of baseline medications plus NLR to predict the effectiveness of nivolumab and pembrolizumab in a real-world clinical setting. Methods: We conducted a single-center retrospective observational study of consecutive patients with advanced NSCLC who received nivolumab or pembrolizumab as first-line, second-line, or beyond treatment between December 2015 and November 2018 at the National Cancer Center Hospital in Japan. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. The drug-based prognostic score for baseline medications plus NLR was weighed based on the regression β coefficients. The multivariable Cox proportional hazard model was used to assess the association between the prognostic score-stratified groups and survival outcomes. Results: In total, 259 patients were evaluated in this study. A prognostic score calculated from the baseline medications plus NLR was used to categorize the patients into good (score 0), intermediate (scores 1–2), and poor (scores 3–6) -prognosis groups. The multivariable Cox proportional hazard model revealed a significant association between the poor-prognosis group and reduced OS. The hazard ratio of OS was 1.75 (95% confidence interval: 1.07–2.99; P = 0.031). In contrast, no association between these prognosis groups and PFS was observed. Conclusions: The findings suggest that the baseline medications with nivolumab or pembrolizumab plus NLR could lead to progressively shorter survival outcomes in patients with advanced NSCLC and could be used as a prognostic index for poor outcomes. However, to ascertain the clinical application of these findings, these concomitant medications need further validation in a large-scale multicenter study.

  • Drug repositioning of antipsychotic drugs for cisplatin-induced pica behavior in mice

    Sekiguchi M., Sagano N., Kawazoe H., Hiraga Y., Jibiki A., Yokoyama Y., Suzuki S., Nakamura T.

    Pharmazie (Pharmazie)  76 ( 10 ) 484 - 487 2021.10

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00317144

     View Summary

    We aimed to clarify whether various antipsychotics ameliorate cisplatin-induced pica behavior in mice using a drug repositioning approach. Mice were administered cisplatin (12.5 mg/kg, i.p.) with or without olanzapine (1 mg/kg, i.p.), asenapine (4 mg/kg, i.p.), mirtazapine (5 mg/kg, i.p.) or standard three-drug antiemetics (granisetron [0.5 mg/kg, i.p.], fosaprepitant [25 mg/kg, i.p.], and dexamethasone [3 mg/kg, i.p.]). Kaolin, food, and water intake, and spontaneous motor activity on the day before and seven consecutive days after the cisplatin administration were measured using a telemetry system. At the primary endpoint, kaolin intake was significantly higher at day three in the cisplatin group than in the pre-treatment and saline groups (p < 0.05). Additionally, kaolin intake was not significantly higher in cisplatin with olanzapine, asenapine, and mirtazapine groups for seven days than in the pre-treatment group. At the secondary endpoint, cisplatin decreased the food and water intake, and spontaneous motor activity in a time-dependent manner. Three antipsychotics failed to improve the cisplatin-induced decrease in food and water intake, and spontaneous motor activity. The findings suggest that prophylactic administration of antipsychotics besides olanzapine may improve cisplatin-induced nausea and vomiting in a delayed phase and de-escalate standard 3-drug antiemetics.

  • 薬学教育モデル・コアカリキュラムに基づく実務実習におけるルーブリック形式の概略評価は実習生のパフォーマンスレベルを評価できるか?

    Hitoshi Kawazoe, Sayo Suzuki, Yui Hiraga, Yuta Yokoyama, Aya Jibiki, Hiroki Iwata, Noriko Kobayashi, Kazuko Fujimoto, Hideo Nakada, Tohru Aomori, Katsunori Yamaura, Tomonori Nakamura, Hiroshi Muramatsu, Tohru Aomori and Mayumi Mochizuki

    Japanese journal of pharmaceutical health care and sciences (Japanese society of pharmaceutical health care and sciences)  47 ( 9 ) 513 - 524 2021.09

    Research paper (scientific journal), Joint Work, Accepted

  • 院内製剤の抗微生物薬,抗ウイルス薬,塩化ナトリウム点眼薬の長期保存における安定性の評価

    武田真美, 横山雄太, 渡邉武明, 平賀ゆい, 地引 綾, 河添 仁, 鈴木小夜, 門田佳子, 中村智徳

    医療薬学 (日本医療薬学会)  47 ( 6 ) 316 - 325 2021.06

    Research paper (scientific journal), Joint Work, Accepted

  • The effect of minimum medical conditions and community pharmacy practice on outcome in hospital pharmaceutical practice

    Keisuke Kiyomiya, Soichiro Tsuda, Yuka Ikebuchi, Sayo Suzuki, Aya Jibiki, Hiroki Iwata, Yuta Yokoyama, Hitoshi Kawazoe, Noriko Kobayashi, Kazuko Fujimoto, Katsunori Yamaura, Tomonori Nakamura, Hiroshi Muramatsu, Tohru Aomori and Mayumi Mochizuki

    Japanese journal of pharmaceutical health care and sciences (Japanese society of pharmaceutical health care and sciences)  46 ( 12 ) 715 - 721 2020.12

    Research paper (scientific journal), Joint Work, Accepted

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • がん薬物治療における職業性暴露対策の新たな動きと未来展望

    Hitoshi Kawazoe, Sayo Suzuki, Yuta Yokoyama, Aya Jibiki, Tomonori Nakamura

    Japanese Journal of Drug Safety 5 ( 2 ) 67 - 76 2019.12

    Introduction and explanation (scientific journal), Joint Work

  • Steroids as cancer medication

    Aya Jibiki, Yuta Yokoyama, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura

    Japanese Journal of Drug Safety 5 ( 1 ) 1 - 13 2019.06

    Introduction and explanation (scientific journal), Joint Work

  • Consideration of cancer treatments and clinical trials for special patient populations

    Sayo Suzuki, Jibiki Aya,Yuta Yokoyama, Hitoshi Kawazoe, Tomonori Nakamura

    Japanese Society of Drug Safety (Japanese Society of Drug Safety)  4 ( 2 ) 83 - 97 2018.12

    Introduction and explanation (scientific journal), Joint Work

  • Toward routine therapeutic drug monitoring of the epidermal growth factor receptor-the tyrosine kinase inhibitors

    Yuta Yokoyama, Sayo Suzuki, Jibiki Aya,Hitoshi Kawazoe, Tomonori Nakamura

    Japanese Society of Drug Safety (Japanese Society of Drug Safety)  4 ( 1 ) 3 - 13 2018.07

    Introduction and explanation (scientific journal), Joint Work

  • クロピドグレルの効果に影響する因子は何か?

    ファルマシア (日本薬学会)  45 ( 11 ) 1142 - 1143 2009.11

    Introduction and explanation (others), Single Work

display all >>

Presentations 【 Display / hide

  • Trends in the use of antidiabetic drugs for glucocorticoid-induced diabetes mellitus in a large-scale hospital database in Japan

    Aya Jibiki, Moeka Kuji, Yuta Yokoyama, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy (Online Conference) , 2022.02, Poster (general), Asian Conference on Clinical Pharmacy

  • Ingenol mebutate inhibits proliferation of pancreatic cancer cells at lower concentration than other established antitumor agents for pancreatic cancer

    Fumihiro Kikuyama, Sayo Suzuki, Haruka Yoshioka, Yu Hirose, Yuta Yokoyama, Aya Jibiki, Hitoshi Kawazoe, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy (Online Conference) , 2022.02, Poster (general), Asian Conference on Clinical Pharmacy

  • A novel assay development and validation for simultaneous quantification of parent compounds and active metabolites of second-/third-generation EGFR-TKIs in human serum using LC-MS/MS, and its clinical application for cancer patients

    Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Ouki Kuniyoshi, Itaru Satou, Naoki Nakaya, Hideo Nakajima, Motonori Kimura, Jun Hakamata, Naoya Suehiro, Hideo Nakada, Shinnosuke Ikemura, Aya Jibiki, Hitoshi Kawazoe, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy (Online Conference) , 2022.02, Poster (general), Asian Conference on Clinical Pharmacy

  • Establishment of a plasma concentration conversion method and genetic polymorphism analyses of dried blood spots using hemaPEN to advance therapeutic drug monitoring in community pharmacies and homes

    Yuta Yokoyama, Mina Hatanaka, Masataka Iwashita, Emi Ishikawa, Aya Jibiki, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy (Online Conference) , 2022.02, Poster (general), Asian Conference on Clinical Pharmacy

  • Implementing the Professionalism Mini-Evaluation Exercise (P-MEX) for assessing students’ medical professionalism during pharmacy practice experience (PPE) in Japan

    Sayo Suzuki, Tsukasa Manabe, Koju Matsuno, Hiroki Makiyama, Shun Kawamoto, Tomoaki Maeda, TatsuyaHirokawa, Yuki Kawai, Fumihiro Kikuyama, Aya Jibiki, Yuta Yokoyama, Hitoshi Kawazoe, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy (Online Conference) , 2022.02, Asian Conference on Clinical Pharmacy

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 更年期障害患者に対する最適な治療薬選択を目指したエストロゲン受容体遺伝子解析

    2021.04
    -
    2022.03

    慶應義塾大学, 慶應義塾2021年度学事振興資金 研究補助, Aya Jibiki, Research grant, Principal Investigator

  • グルココルチコイド誘発性糖尿病患者におけるインスリン離脱困難例の要因分析

    2019.04
    -
    2020.03

    慶應義塾大学, 慶應義塾2019年度学事振興資金 研究補助, 地引 綾, Research grant, Principal Investigator

  • Analysis of factors influencing failure of treatment with harbal medicine for menopausal symptoms

    2018.04
    -
    2021.03

    The Research Foundation for Pharmaceutical Sciences, JIBIKI Aya, Research grant, Principal Investigator

  • グルココルチコイド誘発性糖尿病に対する薬物治療の洗練化と発症予測因子の検討

    2018.04
    -
    2020.03

    Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research, JIBIKI AYA, Research grant, Principal Investigator

     View Summary

    グルココルチコイド(GC)の副作用のうち、GC誘発性糖尿病に着目し、薬物治療の洗練化およびGC誘発性糖尿病の発症予測や早期発見を目指して以下の検討を行う。
    ①GC誘発性糖尿病患者の処方実態について調査し、各種糖尿病治療薬のGC誘発性糖尿病に対する有用性について検討する。
    ②GC内服患者の血中・尿中の11β-Hydroxysteroid dehydrogenase type 1(11β-HSD1)活性を測定し、GC誘発性糖尿病の発現
    群と非発現群において11β-HSD1活性に違いがあるかどうかを比較検討するとともに、11β-HSD1活性とインスリン抵抗性との間に相関があるかどうか検討し、発症予測や早期発見の指標として利用できるか否かを検証する。

 

Courses Taught 【 Display / hide

  • RESEARCH FOR BACHELOR'S THESIS 1

    2021

  • PRIOR LEARNING FOR CLINICAL PRACTICE 3

    2021

  • PRE-CLINICAL TRAINING FOR HOSPITAL & COMMUNITY PHARMACY

    2021

  • PRACTICAL LEARNING ON SUPPORTING THE HEALTH PROMOTION OF COMMUNITY

    2021

  • PHARMACY PRACTICE IN HOSPITAL & COMMUNITY PHARMACY

    2021

display all >>

Courses Previously Taught 【 Display / hide

  • 実務実習事前学習(実習)

    Keio University, 2018, Autumn Semester, Major subject, Laboratory work/practical work/exercise, Outside own faculty (within Keio), 4h, 40people

  • 実務実習事前学習3

    Keio University, 2018, Autumn Semester, Major subject, Lecture, Outside own faculty (within Keio), 160people

    緊急情報の扱い方

  • 実務実習の前に(6)

    Keio University, 2018, Spring Semester, Major subject, Lecture, Outside own faculty (within Keio), 1h, 160people

  • Prior learning for clinical practice 3

    Keio University, 2017, Autumn Semester, Major subject, Lecture, Outside own faculty (within Keio), 1h, 160people

    緊急情報の取り扱い

  • Preclinical practice (6)

    Keio University, 2017, Spring Semester, Major subject, Lecture, Outside own faculty (within Keio), 1h, 152people

    治験薬管理

 

Memberships in Academic Societies 【 Display / hide

  • Japanese Society of Drug Safety, 

    2019
    -
    Present
  • Japan Society for Pharmaceutical Education, 

    2017
    -
    Present
  • 日本老年医学会, 

    2015.05
    -
    2021.03
  • 日本病院薬剤師会, 

    2015
    -
    Present
  • 日本薬剤師会, 

    2015
    -
    Present

display all >>